NCT04350814

Brief Summary

Purpose: Depression affects 12.6% of Canadians at some point in their life. Depression is associated with staggering personal and economic costs. There are several treatments that have been shown to treat episodes of depression when they occur. Unfortunately, more than half who respond to these treatments go on to re-experience an episode of depression. Even with psychological and pharmacological interventions designed to prevent future episodes, relapse and recurrence of the disorder remain alarmingly high. A patient-focused and self-directed intervention that harnesses the effects of an Eastern-influenced concept, called self-compassion, has shown tremendous promise in treating acute depression. Self-compassion is being moved by one's own suffering, and a desire to alleviate such suffering. Objectives: In the proposed project, the investigators will examine whether a self-compassion intervention is effective in preventing relapse/recurrence of depression over a 12-month period among people who are at high risk for relapse. The investigators will also examine whether the intervention works to prevent depression by increasing the innate ability to bounce back from stress, a concept known as resilience. Methodology: 120 participants with a history of depression will be randomly assigned to the self-compassion intervention or a self-assessment reflection condition, and their respective relapse rates will be examined over a period of 12 months. Importance to Research: This will be the first study to examine the effects of self-compassion as a preventive intervention for depression. Impact on health: If successful, this new intervention can be used by thousands of people in Saskatchewan and Canada who are at risk for depression relapse.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
158

participants targeted

Target at P50-P75 for not_applicable depression

Timeline
Completed

Started Mar 2020

Longer than P75 for not_applicable depression

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 14, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 17, 2020

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2024

Completed
Last Updated

May 8, 2024

Status Verified

May 1, 2024

Enrollment Period

3.8 years

First QC Date

April 14, 2020

Last Update Submit

May 7, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Longitudinal Interval Follow-UP Evaluation - Structured Clinical Interview (LIFE-SCID)

    Proportional rates of individuals meeting criteria for major depression episode in accordance with the LIFE-SCID post randomization over 12-months across two conditions. This measure is a diagnostic interview: Outcomes are binary (diagnosis vs. no diagnosis)

    12 Months

  • Weeks to Relapse

    Time in weeks to confirmed MDE relapse during the assessment period This is a linear calculation of how many weeks participants stayed diagnosis free (higher is more weeks without a depressive relapse/recurrence).

    12 Months

  • Scores on the Patient Health Questionnaire - 9 over 12-months

    Differences in depressive symptoms among those randomized to the intervention or active control condition at the 12-month assessment period This measure is a diagnostic interview: Outcomes are binary (diagnosis vs. no diagnosis)

    12 Months

Secondary Outcomes (4)

  • Self-Compassion Scale (SCS)

    Post-intervention, 3, 6, 9, and 12 Months

  • Five-Facet Mindfulness Questionnaire-15

    Post-intervention, 3, 6, 9, and 12 Months

  • Experiences Questionnaire-Decentering

    Post-intervention, 3, 6, 9, and 12 Months

  • Fears of Compassion Scales (FCS)

    Post-intervention, 3, 6, 9, and 12 Months

Study Arms (2)

Self-Compassion Intervention Arm

EXPERIMENTAL

Participants randomized to this condition will receive access to the audio Mindful Self-Compassion self-help intervention. The intervention is 7 weeks in duration (with a pacing of one lesson per week) and participants are asked to complete study measures once each week of the intervention.

Behavioral: Self-Compassion Step by Step

Self-Reflection

ACTIVE COMPARATOR

Participants randomized to this active control condition will be asked to complete study measures at the same assessment intervals as those in the experimental arm. In addition to completing the measures, participants in the Self-Reflection Active Control condition will be asked to reflect on their self-reported symptoms and changes they may have experienced between assessment intervals.

Behavioral: Self-Reflection Active Control

Interventions

This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)

Self-Compassion Intervention Arm

Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.

Self-Reflection

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To be eligible to participate in the study, participants must be: a) 18 years old or older; b) have experienced at least one episode of depression; and c) exhibit elevated residual symptoms of depression-as indicated by a score of 5 or more on the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, \& Williams, 2001). As the majority of people experience both depression and anxiety symptoms concurrently, participants experiencing elevated anxiety symptoms will not be excluded from the study.

You may not qualify if:

  • Participants will be excluded from the study if they indicate: a) a current diagnosis MDD, substance use disorder, psychosis, or mania in accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5; American Psychiatric Association, 2013); b) the presence of major health conditions (e.g., cardiovascular diseases, cancer, hypothyroidism, etc.); and c) currently undergoing psychological or pharmacological treatment at the time of recruitment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Regina

Regina, Saskatchewan, S4S0A2, Canada

Location

DCC Lab

Regina, Canada

Location

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Shadi Beshai, PhD

    University of Regina

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Masking Details
No research assistants involved in participant assessment, nor is the primary investigator, aware of which condition participants are assigned to. This masking will be monitored and conducted by a lab staff member not directly involved in the study.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: The investigators will randomly assign participants to one of two conditions, and monitor their symptoms for 12 months. After the 12-months assessment period is complete, the investigators will offer the intervention to participants assigned to the active control condition to use at their own discretion.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2020

First Posted

April 17, 2020

Study Start

March 1, 2020

Primary Completion

December 1, 2023

Study Completion

May 1, 2024

Last Updated

May 8, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations